Abstract

To report the performance of our self-designed counting algorithm (genome-wide normalised score, namely GWNS) by comparison with the two existing methodologies (z-score and the normalised chromosomal value, namely NCV) and its cross-platform validations. We used theoretical approximations, computer simulations and real experimental data to compare the performance of GWNS with z-score and NCV in our own dataset, and we also did cross-platform comparisons on the different MPSS sequencer platforms (Miseq and GAIIx) manufactured by Illumina. We also looked into the minimal cell-free fetal DNA fraction as well as the lowest read numbers that can achieve a reliable clinical utility. With a fixed level of significance and power, our method requires consistently smaller fetal DNA proportions and total reads compared to the two popular methods – z-scores and NCV. This superiority sustains in theoretic approximations, simulated reads and experimental data collected from maternal plasmas of normal and T21/T18/T13 fetuses. Cross-platform interchangeability between Illumina's GAIIX and Miseq is also demonstrated in our setting. Approximately 4% and 4M reads are the safe lowest limit for safe clinical utility in our setting. Our results demonstrate the benefits of incorporating whole-genome information and can potentially be utilised to detect aneuploidies of other autosomes. GWNS is comparable to the two prevalent counting algorithms in terms of test performance.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.